These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 15389794)

  • 41. Generation of allo-restricted cytotoxic T lymphocytes against malignant glioma by artificial antigen-presenting cells.
    Lu XL; Jiang XB; Liu RE; Zhang FC; Zhao HY
    Cancer Lett; 2007 Oct; 256(1):128-35. PubMed ID: 17719173
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Evaluation of the HER2/neu-derived peptide GP2 for use in a peptide-based breast cancer vaccine trial.
    Mittendorf EA; Storrer CE; Foley RJ; Harris K; Jama Y; Shriver CD; Ponniah S; Peoples GE
    Cancer; 2006 Jun; 106(11):2309-17. PubMed ID: 16596621
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Inhibition of tumor growth with antiangiogenic cancer vaccine using epitope peptides derived from human vascular endothelial growth factor receptor 1.
    Ishizaki H; Tsunoda T; Wada S; Yamauchi M; Shibuya M; Tahara H
    Clin Cancer Res; 2006 Oct; 12(19):5841-9. PubMed ID: 17020992
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Correlation between CD8+ T cells specific for prostate-specific antigen and level of disease in patients with prostate cancer.
    Elkord E; Rowbottom AW; Kynaston H; Williams PE
    Clin Immunol; 2006 Jul; 120(1):91-8. PubMed ID: 16458609
    [TBL] [Abstract][Full Text] [Related]  

  • 45. HLA-A2 and -A24-restricted glypican-3-derived peptide vaccine induces specific CTLs: preclinical study using mice.
    Motomura Y; Ikuta Y; Kuronuma T; Komori H; Ito M; Tsuchihara M; Tsunoda Y; Shirakawa H; Baba H; Nishimura Y; Kinoshita T; Nakatsura T
    Int J Oncol; 2008 May; 32(5):985-90. PubMed ID: 18425324
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Identification of novel CD33 antigen-specific peptides for the generation of cytotoxic T lymphocytes against acute myeloid leukemia.
    Bae J; Martinson JA; Klingemann HG
    Cell Immunol; 2004 Jan; 227(1):38-50. PubMed ID: 15051513
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Increased frequency and responsiveness of PSA-specific T cells after allogeneic hematopoetic stem-cell transplantation.
    Uhlin M; Okas M; Karlsson H; Gertow J; Henningsohn L; Ringdén O; Kärre K; Levitsky V; Mattsson J
    Transplantation; 2009 Feb; 87(4):467-72. PubMed ID: 19307781
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Artificial antigen-presenting cells transduced with telomerase efficiently expand epitope-specific, human leukocyte antigen-restricted cytotoxic T cells.
    Dupont J; Latouche JB; Ma C; Sadelain M
    Cancer Res; 2005 Jun; 65(12):5417-27. PubMed ID: 15958591
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells.
    May RJ; Dao T; Pinilla-Ibarz J; Korontsvit T; Zakhaleva V; Zhang RH; Maslak P; Scheinberg DA
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4547-55. PubMed ID: 17671141
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Peptide-dependent inhibition of alloreactive T-cell response by soluble divalent HLA-A2/IgG molecule in vitro.
    Weng X; Zhong M; Liang Z; Lu S; Hao J; Chen X; Li J; Gong F; Wu X
    Transplantation; 2007 Nov; 84(10):1298-306. PubMed ID: 18049115
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Identification of cyclophilin B-derived peptides capable of inducing histocompatibility leukocyte antigen-A2-restricted and tumor-specific cytotoxic T lymphocytes.
    Tamura M; Nishizaka S; Maeda Y; Ito M; Harashima N; Harada M; Shichijo S; Itoh K
    Jpn J Cancer Res; 2001 Jul; 92(7):762-7. PubMed ID: 11473727
    [TBL] [Abstract][Full Text] [Related]  

  • 52. New peptide vaccine candidates for epithelial cancer patients with HLA-A3 supertype alleles.
    Matsueda S; Takedatsu H; Sasada T; Azuma K; Ishihara Y; Komohara Y; Noguchi M; Shichijo S; Itoh K; Harada M
    J Immunother; 2007 Apr; 30(3):274-81. PubMed ID: 17414318
    [TBL] [Abstract][Full Text] [Related]  

  • 53. New polycomb group protein enhancer of zeste homolog (EZH) 2-derived peptide with the potential to induce cancer-reactive cytotoxic T lymphocytes in prostate cancer patients with HLA-A3 supertype alleles.
    Minami T; Minami T; Shimizu N; Yamamoto Y; De Velasco MA; Nozawa M; Yoshimura K; Harashima N; Harada M; Uemura H
    Int Immunopharmacol; 2015 May; 26(1):133-8. PubMed ID: 25819666
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Identification of CD19 and CD20 peptides for induction of antigen-specific CTLs against B-cell malignancies.
    Bae J; Martinson JA; Klingemann HG
    Clin Cancer Res; 2005 Feb; 11(4):1629-38. PubMed ID: 15746068
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The TAG family of cancer/testis antigens is widely expressed in a variety of malignancies and gives rise to HLA-A2-restricted epitopes.
    Adair SJ; Carr TM; Fink MJ; Slingluff CL; Hogan KT
    J Immunother; 2008 Jan; 31(1):7-17. PubMed ID: 18157007
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Allo-restricted CTLs generated by coculturing of PBLs and autologous monocytes loaded with allogeneic peptide/HLA/IgG1-Fc fusion protein.
    Weng X; Lu S; Zhong M; Liang Z; Shen G; Chen J; Wu X
    J Leukoc Biol; 2009 Mar; 85(3):574-81. PubMed ID: 19112092
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Function analysis of the family-specific CTL induced by peptides derived from IgHV gene framework region of B-cell malignance].
    Guo XL; Zhu P; Liu Y; Liu J; Zhu X
    Zhonghua Xue Ye Xue Za Zhi; 2005 Aug; 26(8):453-7. PubMed ID: 16383233
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A synthetic 15-mer peptide (PCK3145) derived from prostate secretory protein can reduce tumor growth, experimental skeletal metastases, and malignancy-associated hypercalcemia.
    Shukeir N; Arakelian A; Chen G; Garde S; Ruiz M; Panchal C; Rabbani SA
    Cancer Res; 2004 Aug; 64(15):5370-7. PubMed ID: 15289344
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A PR1-human leukocyte antigen-A2 tetramer can be used to isolate low-frequency cytotoxic T lymphocytes from healthy donors that selectively lyse chronic myelogenous leukemia.
    Molldrem JJ; Lee PP; Wang C; Champlin RE; Davis MM
    Cancer Res; 1999 Jun; 59(11):2675-81. PubMed ID: 10363991
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Identification of HLA-DRB1*1501-restricted T-cell epitopes from human prostatic acid phosphatase.
    Klyushnenkova EN; Kouiavskaia DV; Kodak JA; Vandenbark AA; Alexander RB
    Prostate; 2007 Jul; 67(10):1019-28. PubMed ID: 17455230
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.